Multiple Mechanisms of Flaxseed: Effectiveness in Inflammatory Bowel Disease.
Journal
Evidence-based complementary and alternative medicine : eCAM
ISSN: 1741-427X
Titre abrégé: Evid Based Complement Alternat Med
Pays: United States
ID NLM: 101215021
Informations de publication
Date de publication:
2020
2020
Historique:
received:
01
04
2020
accepted:
17
06
2020
entrez:
9
8
2020
pubmed:
9
8
2020
medline:
9
8
2020
Statut:
epublish
Résumé
Aqueous-methanolic crude extracts of Flaxseed (Fs.Cr) and Flaxseed oil were tested against 6% acetic acid- (AA-) induced colitis in BALB/c mice. Microscopic damage parameters of the hematoxylin and eosin-stained and periodic acid-Schiff-alcian blue-stained sections of the colon were scored to be assessed. Possible antispasmodic mechanism was studied on isolated rabbit jejunum, while antibacterial activity was assessed In AA-induced colitis, Flaxseed oil was found to be more effective in reducing mortality and colonic ulcers than Fs.Cr at 500 mg/kg dose. Fs.Cr was more efficacious in increasing mucin content as compared to oil, exhibiting slightly greater anti-inflammatory effect (50% vs 35%) and reducing depth of lesion (55% vs 42.31%, respectively). Antispasmodic activity of Fs.Cr (0.03 and 0.1 mg/ml) was mediated by phosphodiesterase inhibitors (PDEI, possibly PDE-4 subtype) with a resultant increase in cAMP levels. Flaxseed oil PDEI activity was mild (1 and 3 mg/ml). Fs.Cr (0.1 and 0.3 mg/ml) was potent in exhibiting anticholinergic activity, similar to dicyclomine, whereas Flaxseed oil showed anticholinergic effect at 1 and 3 mg/ml. Flaxseed oil (9 and 14 Results of this study, taken together with previous studies, suggest that Flaxseed possesses anti-inflammatory, antibacterial, and antispasmodic action through multiple pathways and thus offers promising potential to be developed for IBD.
Identifiants
pubmed: 32765633
doi: 10.1155/2020/7974835
pmc: PMC7374215
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7974835Informations de copyright
Copyright © 2020 Amber Hanif Palla et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Curr Drug Targets. 2008 May;9(5):395-403
pubmed: 18473768
J Ethnopharmacol. 2015 Jul 1;169:60-8
pubmed: 25889554
Gut. 2001 Jan;48(1):132-5
pubmed: 11115835
Med Sci Monit. 2007 Jul;13(7):PI13-8
pubmed: 17599035
Nat Protoc. 2007;2(3):541-6
pubmed: 17406617
World J Gastroenterol. 2010 Sep 28;16(36):4504-14
pubmed: 20857519
J Gastroenterol. 1995 Apr;30(2):183-8
pubmed: 7773348
J Biol Regul Homeost Agents. 2012 Jul-Sep;26(3):515-26
pubmed: 23034271
J Ethnopharmacol. 2006 May 24;105(3):409-14
pubmed: 16387459
Am J Physiol Gastrointest Liver Physiol. 2014 Jun 15;306(12):G1042-55
pubmed: 24763556
Inflammopharmacology. 2010 Jun;18(3):127-36
pubmed: 20157785
J Nutr Biochem. 2015 Dec;26(12):1632-40
pubmed: 26350254
J Exp Med. 1995 Nov 1;182(5):1281-90
pubmed: 7595199
Gen Pharmacol. 1991;22(1):177-81
pubmed: 1904831
J Pediatr Gastroenterol Nutr. 2005 Apr;40 Suppl 1:S32
pubmed: 15805842
J Pharmacol Sci. 2005 Jul;98(3):275-82
pubmed: 15988126
Br J Pharmacol. 2006 Jan;147 Suppl 1:S252-7
pubmed: 16402111
Nature. 2007 Jul 26;448(7152):427-34
pubmed: 17653185
Inflamm Allergy Drug Targets. 2008 Sep;7(3):129-35
pubmed: 18782019
Invest New Drugs. 2008 Oct;26(5):417-24
pubmed: 18264679
J Ethnopharmacol. 2008 Mar 28;116(3):528-38
pubmed: 18289813
Digestion. 1978;17(2):135-50
pubmed: 627326
Complement Ther Med. 2019 Oct;46:36-43
pubmed: 31519285
Biol Pharm Bull. 2007 Jan;30(1):145-9
pubmed: 17202675
Inflammopharmacology. 2011 Feb;19(1):45-52
pubmed: 20602175
J Ethnopharmacol. 2015 Feb 3;160:61-8
pubmed: 25433250
J Pharmacol Exp Ther. 1989 Oct;251(1):199-206
pubmed: 2552074
Drugs. 1997 Nov;54(5):679-708
pubmed: 9360057
Gastroenterol Res Pract. 2013;2013:431231
pubmed: 23737764
Arch Int Pharmacodyn Ther. 1963;143:299-330
pubmed: 13996119
Am J Clin Nutr. 2006 Jun;83(6 Suppl):1526S-1535S
pubmed: 16841863
Int Immunopharmacol. 2016 Sep;38:153-66
pubmed: 27280586
Dig Dis Sci. 2011 May;56(5):1460-71
pubmed: 21082352
Gut. 1990 May;31(5):539-44
pubmed: 2161781
Br J Pharmacol Chemother. 1959 Mar;14(1):48-58
pubmed: 13651579
J Antimicrob Chemother. 2008 Sep;62(3):634-5
pubmed: 18552339
Pharmacol Rep. 2014 Feb;66(1):169-73
pubmed: 24905324
Phytother Res. 2000 Sep;14(6):436-42
pubmed: 10960898
Gut Pathog. 2015 Jan 29;7(1):2
pubmed: 25653719
Acta Gastroenterol Latinoam. 1995;25(3):137-44
pubmed: 8600700
BMC Complement Altern Med. 2012 Mar 09;12:14
pubmed: 22400899